Comparison of Limus and Paclitaxel Drug–Coated Balloons, Second-Generation or Newer Drug-Eluting Stents, and Balloon Angioplasty: A Network Meta-Analysis of Randomized Controlled Trials
Pooled resultResult — go to the resultRelative risk 1.22 95% CI 0.86–1.73Authors' conclusion
No significant differences were observed in MACE or its components between limus and paclitaxel DCBs, albeit with limited statistical power. Furthermore, DCB and second-generation or newer drug-eluting stents yielded similar outcomes though power was limited, especially for other de novo CAD.
Study context
- Population
- Patients with coronary artery disease (CAD)
- Participants
- 10,219 patients · 39 RCTs
- Comparison
- Limus DCB vs Paclitaxel DCB
- Outcome
- Trial-defined MACE, typically a composite of death, MI or target lesion revascularization
Methodological detailssubgroup analyses
- Subgroup analyses
Pooled result
As reported in the abstract
Relative risk
1.22
95% CI 0.86–1.73
Limus DCB vs Paclitaxel DCB
RR 1.22 (95% CI 0.86–1.73)
Further pooled results
MACE in subgroups: in-stent restenosis, small-vessel CAD, other de novo CAD (subgroup)
- Results consistent across subgroup analyses
Original publication
Comparison of Limus and Paclitaxel Drug–Coated Balloons, Second-Generation or Newer Drug-Eluting Stents, and Balloon Angioplasty: A Network Meta-Analysis of Randomized Controlled Trials. Circ Cardiovasc Interv. Published 27 October 2025. doi:10.
Summarised from the published abstract; every number is checked against it